Recently, the New Zealand patent application "PTH prodrugs" – a global counterpart patent application filed and owned by Ascendis Pharma Growth Disorders AG, with the theme "PTH prodrugs" – has been granted. Previously, two patents ...
Recently, the U.S. patent application "Camera module, molded circuit board assembly, molded photosensitive assembly and manufacturing method thereof" — a global counterpart patent application filed and owned by Ningbo Sunny Opotech ...
Recently, the Supreme People's Court issued the Administrative Judgment (2022) Zui Gao Fa Zhi Min Zhong No. 883 in the administrative dispute over the invalidation of utility model patent rights involving Qingdao XX Heavy Industry Co., Ltd., the ...
Recently, the U.S. patent application "Acylated glp-1 derivative" — a global counterpart patent application filed and owned by Sciwind Biotherapeutics, with the theme "Acylated GLP-1 Derivatives" — has been granted. Previously ...
Recently, the U.S. patent application "Antibody targeting IL-13RA2 and use thereof" — a global counterpart patent application filed and owned by CARsgen Therapeutics and Clergy Medicine, with the theme "Antibody Targeting IL-13RA2 and ...
Recently, the Nanjing Intermediate People's Court of Jiangsu Province issued a civil ruling in the dispute over infringement of appearance design patent rights between Qin Moumou and Beijing Yining E-Commerce Co., Ltd. (hereinafter referred to as ...
On January 19, 2023, the National Intellectual Property Administration issued the Examination Decision on Invalidation Request No. 60416, deciding to maintain the validity of Chinese Invention Patent No. 200880121086.6 (invention title: "Method ...
Recently, the China National Intellectual Property Administration (CNIPA) issued a Notice of Closure of Invalidation Proceedingfor the invalidation case with case number 4W114288 (hereinafter referred to as “this case”), informing the patentee ...
Recently, PanTai Biotechnology (Zhejiang) Co., Ltd. (hereinafter referred to as “PanTai Bio”) announced the completion of a Series A financing round of tens of millions of RMB, exclusively invested by YuanSheng Venture Capital, with QuShi Capital ...
Recently, Jiangsu Qyuns Therapeutics Co., Ltd. obtained grant authorization in Australia for its patent application corresponding to the family of “Anti-Human Interleukin-4 Receptor Alpha Monoclonal Antibody and Use Thereof” (Australian title ...
86-10-62167650
mail@caihelaw.com
20th Floor, Guoxing Building, No. 22 Shou Du Ti Yu Guan Nan Road, Haidian District, Beijing, China (Exit C, Bai Shi Qiao Nan Station, Metro Line 6 / Line 9)
